首页|奥希替尼相关性间质性肺疾病28例文献分析

奥希替尼相关性间质性肺疾病28例文献分析

扫码查看
目的 分析奥希替尼相关性间质性肺疾病(ILD)的发生规律和特点。方法 检索2015年11月至2023年6月中国知网、维普、万方及PubMed数据库收载的奥希替尼相关ILD的个案报道,提取相关数据进行分析。结果 共筛选出个案报道25篇,涉及奥希替尼相关性ILD患者28例,男性14例,女性14例,年龄32~86岁。4例患者在奥希替尼治疗前序贯使用了 PD-1抑制剂,21例患者在用药3个月内发生ILD,25例患者停药或减量后症状缓解,3例患者死亡。结论 奥希替尼应用3个月内需密切防范ILD的发生,尤其是序贯使用PD-1抑制剂的患者。出现ILD后立即停药是改善转归的关键。
Analysis of 28 cases of osimertinib related interstitial lung disease based on literature review
AIM To analyze the general patterns and characteristics of osimertinib related interstitial lung disease(ILD).METHODS The case reports of osimertinib related ILD from CNKI,VIP,Wanfang and PubMed database between November 2015 to June 2023 were searched and analyzed.RESULTS A total of 25 case reports were enrolled,involving 28 cases with ILD,14 male and 14 female cases,aged 32 to 86 years old.PD-1 inhibitors were used sequentially in 4 patients before administering osimertinib,21 patients developed ILD in 3 months,25 patients experienced symptom relief after discontinuation reduction medication,and 3 patients died.CONCLUSION ILD should be closely guarded in 3 months of the application of osimertinib,especially these patients who received the sequence treatment of PD-1 inhibitors.The key to improving the prognosis is to stop using osimertinib immediately after ILD.

osimertinibinterstitial lung diseasecase report

傅振玲、孙华瑜

展开 >

衢州市人民医院药学部,浙江衢州 324000

奥希替尼 间质性肺疾病 病例报告

2024

中国新药与临床杂志
中国药学会 上海市食品药品监督管理局科技情报研究所

中国新药与临床杂志

CSTPCD北大核心
影响因子:0.967
ISSN:1007-7669
年,卷(期):2024.43(8)